for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inovio Pharmaceuticals Inc

INO.O

現在値

2.01USD

変化

-0.04(-1.95%)

出来高

2,140,874

本日のレンジ

1.99

 - 

2.07

52週レンジ

1.38

 - 

7.77

∙ 約20分前の相場を表示しています。

適時開示

INOVIO Reports Financial Results, Highlights For The Third Quarter 2022

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR THE THIRD QUARTER 2022.INOVIO PHARMACEUTICALS INC Q3 LOSS PER SHARE $0.15.INOVIO PHARMACEUTICALS INC Q3 REVENUE $9.2 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.30, REVENUE VIEW $623170.00 -- REFINITIV IBES DATA.INOVIO PHARMACEUTICALS INC- EXPECTS CASH RUNWAY TO EXTEND INTO Q1 OF 2025.

Inovio Pharmaceuticals Reports Positive Interim Phase 1/2 Results For Ino-3107 For The Treatment Of Recurrent Respiratory Papillomatosis

Oct 13 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS POSITIVE INTERIM PHASE 1/2 RESULTS FOR INO-3107 FOR THE TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS.INOVIO PHARMACEUTICALS INC - INO-3107 WAS FOUND TO BE WELL-TOLERATED AND IMMUNOGENIC.INOVIO PHARMACEUTICALS - INO-3107 SHOWED STATISTICAL SIGNIFICANCE BASED ON CLINICAL ENDPOINT OF REDUCTION IN OVERALL NUMBER OF SURGICAL INTERVENTIONS VERSUS LAST YEAR.INOVIO PHARMACEUTICALS INC - WHILE TWO SERIOUS ADVERSE EVENTS WERE REPORTED, THESE WERE ALSO DEEMED UNRELATED TO INO-3107.INOVIO PHARMACEUTICALS INC - RESULTS FROM SECOND COHORT OF 11 PATIENTS FROM INO-3107 TRIAL ARE EXPECTED IN FIRST HALF OF 2023.

Inovio Reports Second Quarter 2022Financial Results

Aug 9 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR THE SECOND QUARTER 2022.INCREASED CASH RUNWAY INTO Q3 2024 WITH COST-SAVINGS AND CORPORATE RESTRUCTURING EFFORTS.ANNOUNCED A CORPORATE REORGANIZATION DESIGNED TO EXTEND ITS CASH RUNWAY.TOTAL REVENUE WAS $784,000 FOR THREE MONTHS ENDED JUNE 30, 2022, COMPARED TO $273,000.Q2 LOSS PER SHARE $0.46.

Inovio Announces Corporate Reorganization

July 19 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO ANNOUNCES CORPORATE REORGANIZATION TO REDUCE OPERATIONAL EXPENSES AND FOCUS ON OPPORTUNITIES TO BRING THE PROMISE OF DNA MEDICINES TO PATIENTS.INOVIO PHARMACEUTICALS INC - CHANGES EXPECTED TO REDUCE OPERATIONAL EXPENSES AND EXTEND COMPANY'S CASH RUNWAY INTO Q3 OF 2024.INOVIO PHARMACEUTICALS INC - REORGANIZATION, INCLUDES AN 18% WORKFORCE REDUCTION IN FULL-TIME EMPLOYEES AND 86% REDUCTION IN CONTRACTORS.INOVIO PHARMACEUTICALS INC - REORGANIZATION, IS EXPECTED TO REDUCE OPERATING EXPENSES BY APPROXIMATELY 30% OVER NEXT 18 MONTHS.INOVIO PHARMACEUTICALS INC - INOVIO EXPECTS A ONE-TIME RESTRUCTURING CHARGE OF APPROXIMATELY $1.6 MILLION IN Q3 OF 2022..

Inovio Pharmaceuticals Reports Qtrly Loss Per Share Of $0.36

May 10 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PHARMACEUTICALS INC- QTRLY LOSS PER SHARE $0.36.INOVIO PHARMACEUTICALS INC- QTRLY TOTAL REVENUES $199,074 VERSUS $371,120.

Inovio Appoints Jacqueline Shea As CEO

May 10 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO ANNOUNCES THE APPOINTMENT OF JACQUELINE SHEA, PH.D., AS CHIEF EXECUTIVE OFFICER.INOVIO PHARMACEUTICALS INC - SHEA SUCCEEDS J. JOSEPH KIM IN THESE ROLES.

Inovio Reports Q1 Loss Per Share Of $0.36

May 10 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROGRAM DEVELOPMENTS.Q1 LOSS PER SHARE $0.36.Q1 REVENUE $199,000.Q1 EARNINGS PER SHARE VIEW $-0.34, REVENUE VIEW $671670.00 -- REFINITIV IBES DATA.

Inovio Reports Fourth Quarter 2021 And Year-End Financial Results

March 1 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS FOURTH QUARTER 2021 AND YEAR-END FINANCIAL RESULTS.AS OF DECEMBER 31, 2021, CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $401.3 MILLION.QTRLY LOSS PER SHARE $0.50.Q4 EARNINGS PER SHARE VIEW $-0.32 -- REFINITIV IBES DATA.

Inovio Highlights Key Updates On Phase 3 Program For VGX-3100

Dec 14 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO HIGHLIGHTS KEY UPDATES ON PHASE 3 PROGRAM FOR VGX-3100, ITS DNA-BASED IMMUNOTHERAPY FOR THE TREATMENT OF CERVICAL HSIL CAUSED BY HPV-16 AND/OR HPV-18.INOVIO PHARMACEUTICALS INC - COMPLETES ENROLLMENT OF REVEAL2.INOVIO PHARMACEUTICALS INC -.INOVIO PHARMACEUTICALS INC - LONG-TERM DATA FAVORABLE FROM REVEAL1.INOVIO PHARMACEUTICALS INC - FIRST PARTICIPANT HAS BEEN DOSED IN PHASE 3 TRIAL OF VGX-3100 FOR CERVICAL HSIL IN CHINA.INOVIO PHARMACEUTICALS INC - ADVANCING ITS PARTNERSHIP WITH QIAGEN TO CO-DEVELOP A LIQUID BIOPSY-BASED DIAGNOSTIC PRODUCT.INOVIO PHARMACEUTICALS INC - ANTICIPATES HAVING ADDITIONAL INFORMATION ON ITS BIOMARKER DEVELOPMENT IN 2022.

Inovio Posts Q3 Loss Per Share Of $0.29

Nov 9 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.29.DOSING FOR INNOVATE PHASE 3 SEGMENT IS UNDERWAY AND WE AIM TO HAVE INTERIM EFFICACY DATA IN THE FIRST HALF 2022.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up